G6PD

Glucose-6-Phosphate Dehydrogenase

Großes Blutbild

Zuletzt geprüft: 7. April 2026. Quellenansatz: Standardkontext zur Laborinterpretation, allgemeine medizinische Referenzmaterialien sowie öffentliche Gesundheits- oder klinische Leitlinien, sofern relevant.

Was ist Glucose-6-Phosphate Dehydrogenase?

Glucose-6-phosphate dehydrogenase (G6PD) is a cytoplasmic enzyme present in all cells but particularly critical in red blood cells. It catalyzes the first and rate-limiting step of the pentose phosphate pathway (hexose monophosphate shunt), converting glucose-6-phosphate to 6-phosphogluconate while reducing NADP+ to NADPH. NADPH is essential for regenerating reduced glutathione (GSH), the primary antioxidant defense in red blood cells. Unlike most cells, mature red blood cells lack mitochondria and a nucleus, making the pentose phosphate pathway their sole source of NADPH. Without adequate G6PD activity, red blood cells cannot neutralize oxidative stress, leading to oxidative damage to hemoglobin (forming Heinz bodies), membrane lipid peroxidation, and ultimately hemolysis.

G6PD deficiency is the most common human enzyme deficiency, affecting approximately 400–500 million people worldwide. It is X-linked recessive, primarily affecting males, though heterozygous females can also be symptomatic due to X-inactivation (lyonization). The deficiency is most prevalent in populations from malaria-endemic regions—Africa, the Mediterranean, the Middle East, and Southeast Asia—because G6PD deficiency confers partial resistance to Plasmodium falciparum malaria, a classic example of balanced polymorphism. Over 200 G6PD variants have been identified, with varying degrees of enzyme deficiency and clinical severity.

Warum der Wert wichtig ist

G6PD deficiency is a major cause of drug-induced hemolytic anemia, favism (hemolysis triggered by fava beans), and neonatal jaundice. The clinical significance lies in prevention: identifying G6PD-deficient individuals before prescribing oxidative medications—including primaquine, dapsone, rasburicase, nitrofurantoin, and certain sulfonamides—can prevent potentially life-threatening hemolytic crises. G6PD testing is also recommended before prescribing rasburicase for tumor lysis syndrome, as methemoglobinemia and hemolysis can occur. In neonates, unrecognized G6PD deficiency is a leading cause of severe hyperbilirubinemia and kernicterus in endemic regions.

Normale Referenzbereiche

GruppeBereichEinheit
Adults (quantitative)4.6–13.5U/g Hb
Qualitative (fluorescent spot test)Normal fluorescence
NeonatesMay be higher than adult valuesU/g Hb

Referenzbereiche können je nach Labor variieren. Vergleichen Sie Ihre Ergebnisse immer mit den Bereichen Ihres Testlabors.

Was hohe G6PD-Werte bedeuten

Häufige Ursachen

  • Reticulocytosis (young red blood cells have higher G6PD activity)
  • Recent hemolytic episode (testing during recovery may show falsely normal/elevated levels)
  • Chronic myeloproliferative disorders
  • Hyperthyroidism
  • Megaloblastic anemia after treatment (reticulocyte surge)

Mögliche Symptome

  • Elevated G6PD activity itself does not cause symptoms
  • May mask underlying G6PD deficiency if tested during reticulocytosis

Was zu tun ist: Elevated G6PD activity is not clinically concerning and usually reflects reticulocytosis. However, if G6PD deficiency is suspected and the patient has recently had a hemolytic episode, the high reticulocyte count can falsely normalize the G6PD level. Repeat testing 2–3 months after the acute episode when the reticulocyte count has normalized to obtain an accurate baseline G6PD level.

Was niedrige G6PD-Werte bedeuten

Häufige Ursachen

  • G6PD deficiency (X-linked genetic condition)
  • WHO Class I: chronic non-spherocytic hemolytic anemia (severe, <10% activity)
  • WHO Class II: Mediterranean and Asian variants (severe, <10% activity, intermittent hemolysis)
  • WHO Class III: African variant (A-) (moderate, 10–60% activity, usually mild)

Mögliche Symptome

  • Acute hemolytic anemia triggered by oxidative stress (medications, fava beans, infections)
  • Dark urine (hemoglobinuria)
  • Jaundice and pallor
  • Fatigue and tachycardia
  • Back or abdominal pain during acute hemolysis
  • Neonatal jaundice (in severe variants)
  • Chronic hemolytic anemia (rare, severe variants)

Was zu tun ist: G6PD deficiency has no cure, but hemolytic episodes are preventable. Provide the patient with a list of medications and substances to avoid (primaquine, dapsone, rasburicase, nitrofurantoin, fava beans, naphthalene mothballs). Treat acute hemolysis with hydration, monitoring, and blood transfusion if severe. Screen neonates at risk for severe jaundice. Educate the patient and family, and ensure the deficiency is documented in medical records. Genetic counseling may be appropriate for family planning.

Wann wird ein G6PD-Test empfohlen?

  • Before prescribing oxidant medications (primaquine, dapsone, rasburicase, nitrofurantoin)
  • In neonates with unexplained or severe jaundice, especially in at-risk ethnic groups
  • When evaluating acute hemolytic anemia with Heinz bodies or bite cells on blood smear
  • In patients with recurrent episodes of hemolysis triggered by drugs, infections, or foods
  • In males of African, Mediterranean, Middle Eastern, or Southeast Asian descent before certain medications

Häufig gestellte Fragen

G6PD deficiency evolved as a survival advantage against Plasmodium falciparum malaria. Red blood cells with reduced G6PD activity create an inhospitable environment for the malaria parasite, which depends on the host cell's antioxidant pathways. This "balanced polymorphism" means the gene persisted in populations where malaria was endemic—sub-Saharan Africa (10–25% prevalence), the Mediterranean (up to 20%), the Middle East, and Southeast Asia. The trade-off is susceptibility to oxidative hemolysis.
Yes, though it is less common and often less severe. G6PD is X-linked, so males (with one X chromosome) are either fully deficient or normal. Females have two X chromosomes, and due to random X-inactivation (lyonization), heterozygous females are genetic mosaics with a mixture of G6PD-normal and G6PD-deficient red blood cells. Most heterozygous females have sufficient enzyme activity to prevent significant hemolysis, but some—depending on the pattern of X-inactivation—can be as severely affected as hemizygous males. Homozygous females are fully deficient.
During acute hemolysis, the oldest red blood cells (with the lowest G6PD activity) are preferentially destroyed, leaving younger reticulocytes with higher G6PD activity. This can produce a falsely normal test result—the very cells that would show deficiency have been destroyed. For accurate results, wait at least 2–3 months after an acute hemolytic episode so that the red blood cell population returns to a steady state with a normal age distribution. If urgent results are needed, molecular genetic testing can confirm the diagnosis regardless of timing.

Verwandte Biomarker

HgbHämoglobinTBILBilirubinHpHaptoglobinLDHLaktatdehydrogenase

Weiterführende Inhalte

Erkrankungen

Anämie →

Quellen- und Prüfungsansatz

Biomarker-Glossarseiten sind erklärende Bildungsinhalte und sollten immer zusammen mit den Referenzbereichen und Kommentaren Ihres Labors sowie Ihrer Ärztin oder Ihres Arztes interpretiert werden. Mehr zu unseren redaktionellen Standards und unserem Prüfprozess finden Sie in unserer Redaktionsrichtlinie und Prüfprozess für Inhalte.

Möchten Sie Ihre G6PD-Werte analysieren lassen?

Laden Sie Ihre Laborwerte hoch und erhalten Sie sofort eine KI-gestützte Einordnung aller Biomarker.

Laborwerte hochladen →

Medizinischer Hinweis: Diese Informationen dienen nur Bildungszwecken und ersetzen keine professionelle medizinische Beratung, Diagnose oder Behandlung. Referenzbereiche können zwischen Laboren variieren. Besprechen Sie die Interpretation Ihrer konkreten Testergebnisse immer mit Ihrer medizinischen Fachperson.

Hinweis: SymptomGPT ist kein medizinisches Diagnosetool und ersetzt keine medizinische Beratung. Wenden Sie sich immer an qualifiziertes medizinisches Fachpersonal. Wenn Sie einen medizinischen Notfall haben, rufen Sie sofort Ihre örtliche Notrufnummer an.